May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
COX–2 Expression in Human Uveal Melanoma: Implication for Prognosis
Author Affiliations & Notes
  • L.M. Cryan
    Department of Clinical Pharmacology, RCSI, Dublin, Ireland
  • L. Paraoan
    School of Clinical Sciences, Unit of Ophthalmology, University of Liverpool, Liverpool, United Kingdom
  • P. Hiscott
    School of Clinical Sciences, Unit of Ophthalmology, University of Liverpool, Liverpool, United Kingdom
  • I. Grierson
    School of Clinical Sciences, Unit of Ophthalmology, University of Liverpool, Liverpool, United Kingdom
  • B.E. Damato
    St Pauls Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
  • M. Farrell
    Department of Neuroscience, Beaumont Hospital, RCSI, Dublin, Ireland
  • G. Doherty
    Department of Molecular Medicine,
    Conway Institute of Biomolecular and Biomedical Research, UCD, Dublin, Ireland
  • D.J. Fitzgerald
    Department of Molecular Medicine,
    Conway Institute of Biomolecular and Biomedical Research, UCD, Dublin, Ireland
  • C. O'Brien
    Department of Ophthalmology,
    Conway Institute of Biomolecular and Biomedical Research, UCD, Dublin, Ireland
  • Footnotes
    Commercial Relationships  L.M. Cryan, None; L. Paraoan, None; P. Hiscott, None; I. Grierson, None; B.E. Damato, None; M. Farrell, None; G. Doherty, None; D.J. Fitzgerald, None; C. O'Brien, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4619. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L.M. Cryan, L. Paraoan, P. Hiscott, I. Grierson, B.E. Damato, M. Farrell, G. Doherty, D.J. Fitzgerald, C. O'Brien; COX–2 Expression in Human Uveal Melanoma: Implication for Prognosis . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4619.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Cyclooxygenase, the enzyme which catalyses the rate limiting step in the formation of prostaglandins, exists as two isoforms, COX–1 and COX–2. COX–1 is constitutively expressed in many tissues, whereas COX–2 is termed the inducible isoform and is overexpressed in inflammatory and neoplastic disease states. Prostaglandins derived from COX–2 are believed to mediate many of the proliferative, invasive and metastatic properties of tumour cells, and selective inhibitors of COX–2 attenuate metastasis in many pre–clinical models. The aim of this study was to examine the expression of COX–2 and its prognostic value in uveal melanoma. Methods: Paraffin–embedded sections from 17 clinicopathologically well–characterised cases of primary uveal melanoma were immunohistochemically stained for COX–2. In 10 cases metastatic disease led to death, and the mean follow–up of non–metastasised patients was 10 years. The expression of COX–2 was analysed with respect to both intensity and the percentage of cells stained, by 3 independent observers masked to the follow–up of patients. A COX–2 score incorporating both the intensity and % of cells stained was calculated for each sample. Statistical analyses included Kaplan–Meier survival curves, Log–Rank test, Fischers Exact test and Spearmans rank correlation coefficient. Results: Of the 17 specimens analysed 15 (88.2%) contained moderate or intense positive immunoreactivity for COX–2, and significant variation in the percentage of cells stained was observed between samples. Kaplan–Meier analysis showed a statistically significant association (P = 0.04) between COX–2 expression (COX–2 score) and metastatic death. Conclusions: Upregulation of COX–2 expression appears to be associated with poor prognosis in uveal melanoma. Further studies, extended on a larger sample of specimens, are warranted to investigate the molecular mechanism of COX–2 in uveal melanoma. Selective COX–2 inhibitors, currently in widespread clinical use for other diseases, may represent a realistic adjuvant therapy for uveal melanoma.

Keywords: eicosanoids • immunohistochemistry • melanoma 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×